423 related articles for article (PubMed ID: 10665481)
1. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
2. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
4. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Senderowicz AM
Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical development of cyclin-dependent kinase modulators.
Senderowicz AM; Sausville EA
J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.
Kelland LR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2903-11. PubMed ID: 11093360
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
Wang LM; Ren DM
Mini Rev Med Chem; 2010 Oct; 10(11):1058-70. PubMed ID: 21047304
[TBL] [Abstract][Full Text] [Related]
11. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
12. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Sausville EA
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials referral resource. Flavopiridol.
Colevas D; Blaylock B; Gravell A
Oncology (Williston Park); 2002 Sep; 16(9):1204-5, 1210-2, 1214. PubMed ID: 12380947
[No Abstract] [Full Text] [Related]
15. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Senderowicz AM
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Senderowicz AM
Prog Drug Res; 2005; 63():183-206. PubMed ID: 16265881
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
